Peptic Ulcer Drugs Market

Global Peptic Ulcer Drugs Market Size (2024 to 2029)

The global peptic ulcer drugs market was valued at around USD 4.92 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 2.64% from 2024 to 2029 and be worth USD 5.75 billion by 2029 from USD 5.05 billion in 2024.

A peptic ulcer is a breakage in the inner surface of the stomach or the upper part of the intestine in the gastrointestinal tract. Ulcers form when the protective wall of the intestine or stomach is broken. When the lining is interrupted, the acidic gastric juices that contain hydrochloric acid and an enzyme called pepsin irritate the stomach and cause inflammation around it, leading to ulcers. Peptic ulcers represent a group of ulcerative disorders such as gastritis, gastric ulcers, and duodenal ulcers, or gastroesophageal reflux disease (GERD). Treatment of peptic ulcers is carried out with drugs such as proton pump inhibitors (PPIs), competitive potassium acid inhibitors, antacids, H2 antagonists, antibiotics, and ulcer-protective drugs such as sucralfate.

MARKET DRIVERS

The peptic ulcer drugs market is expected to grow at a rapid rate during the forecast period.

Lifestyle factors such as increased consumption of soft drinks, alcoholism, fatty foods, and stress can cause peptic ulcers, which is expected to accelerate the growth of the global peptic ulcer drugs market. Peptic ulcers can cause disturbance in lifestyle for older people due to loss of appetite, chronic fatigue, and lethargy. Hence, the increase in this senior population is a key factor that is expected to drive the market during the forecast period. In addition, the growing employment rates and increasing levels of stress associated with it support the growth of the market. Peptic ulcers can be extremely painful and uncomfortable. It can cause nausea, heartburn, and bloating and if not treated for a long time it can even cause severe problems like breathing difficulty, passing blood in the stool, vomiting blood, etc., therefore, the severe symptoms lead to a requirement for better peptic ulcer treatments. 

The growing patient population of chronic diseases and increasing consumption of drugs such as aspirin, ibuprofen and other inflammatory drugs are boosting the peptic ulcer drugs market growth.

According to the American Cancer Society, In the U.S, 32,500 people had stomach cancer in 2018, these numbers rose to 35,500 cases in 2020, while nearly 11,500 people are estimated to die due to complications. According to a 2021 recent study conducted at Harvard University, more than 8 million people suffer from peptic ulcers each year. The increasing number of cases of people suffering from gastrointestinal ulcers is driving the demand for peptic ulcer drugs across the world. In addition, the growing healthcare awareness and availability of peptic ulcer drugs are expected to contribute to market growth in the coming years.

Growing demand for the use of non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin, paracetamol, and others and growing awareness about peptic ulcers and their treatment options are factors expected to trigger the growth of the peptic ulcer drugs market. The growing cases of peptic ulcers worldwide also support the need for the market. For example, annually, around 4 million people suffer from peptic ulcers, according to the National Institute of Health. Furthermore, the several new treatments being approved for peptic ulcers drive the market growth. For example, Dartisla ODT, which has anticholinergic properties, was approved as an adjunct to cure peptic ulcers by the FDA in December 2021. 

MARKET RESTRAINTS

However, the side effects of long-term use of PPIs, changes in government policies, the loss of market exclusivity for most peptic ulcer drugs, and the limited R&D efforts in the field of peptic ulcer drugs are factors that will hamper the growth of peptic ulcer drugs market across the world. The reimbursement of medical costs related to certain tests and medicines in some countries, especially in APAC regions, is challenging the growth of the peptic ulcer drugs market.

REPORT COVERAGE

SEGMENTAL ANALYSIS

Global Peptic Ulcer Drugs Market Analysis By Drug Type

The antibiotics segment is expected to dominate the market during the forecast period. The extensive use of antibiotics for ulcers from helicobacter pylori infections and the use of antibiotics as the first line of treatment for ulcers support the growth of the segment in the market. The antibiotics amoxicillin, clarithromycin, and metronidazole are heavily used in treatment procedures.

The proton pump inhibitors segment is also expected to grow during the forecast period due to the growing use in ulcer treatment. Antibiotics and proton pump inhibitors are always used in a combination treatment and these inhibitors prevent the stomach lining from releasing acids. Therefore, the effectiveness of the procedure supports market growth. 

Global Peptic Ulcer Drugs Market Analysis By Ulcer Type

The duodenal ulcer segment is expected to dominate the market during the forecast period due to the growing cases of ulcers in the duodenum. The growing prevalence of therapeutic ulcer procedures and awareness regarding the need for treatment supports the growth of the market. The gastric ulcer segment is also expected to grow due to growing gastric problems like gastroenteritis and acidity.

REGIONAL ANALYSIS

Geographically, the North American peptic ulcer drugs market and Europe peptic ulcer drugs market collectively accounted for 67% of the total revenue share in the global peptic ulcer drugs market in 2023. The U.S. peptic ulcer drug market was estimated at USD 1.4 billion in 2020, while Canada is estimated to grow at a CAGR of 2.55% during the forecast period. North America was worth USD 2.06 billion in 2020 and is expected to hold the largest market share in the coming years. This market growth in the region is due to the increase in incidences of peptic ulcer patients in the United States.

The Asia-Pacific peptic ulcer drugs market regional market held 23% of the overall peptic ulcer drug market share and this trend is estimated to gain similar growth during the forecast period, owing to the increased case of recurrent peptic ulcers in patients. China will be one of the fastest-growing Asian countries in the APAC region. Led by countries like Australia, India, and South Korea, the Asia-Pacific market is expected to reach USD 698 million by 2026.

The MEA peptic ulcer drugs market is expected to grow at a slow and steady rate during the forecast period, owing to the low accessibility of peptic ulcer drugs and poor healthcare infrastructure in the region. Other regional markets such as Saudi Arabia and UAE, will be growing at a CAGR of 2.8% and 2.1% respectively over the forecast period.

In Europe, Germany is expected to grow at a 2.8% CAGR during the forecast period. The growing awareness of peptic ulcers in humans is one of the emerging trends in the European peptic ulcer drugs market in the coming years. The growth of the European market can be attributed to the increasing number of patients suffering from peptic ulcers as well as increasing healthcare spending in European countries such as Germany, the UK, and France. The market demand in Germany is mainly due to the easy availability of medicines and effective treatment options for peptic ulcers.

On the other hand, the Latin American peptic ulcer drugs market is expected to occupy a moderate share in the global market during the forecast period in the global market. This is attributable to factors such as lesser healthcare spending in countries like Peru, Chile, and Ecuador over the forecast period.

KEY PLAYERS IN THE GLOBAL PEPTIC ULCER DRUGS MARKET

Novartis AG, Daiichi Sankyo Company Limited, Acetelion Ltd, Boehringer Ingelheim, Sanofi S.A., Astra Zeneca, Ranbaxy Laboratories Limited, Inc., Takeda Pharmaceuticals Company Limited, Pfizer Inc., Helicure AB and Eumedica Pharmaceuticals are some of the companies currently dominating the global peptic ulcer drugs market and profiled in this report.

RECENT HAPPENINGS IN THE MARKET

• In October 2019, Novitium Pharma LLC recalled ranitidine hydrochloride capsules in the United States due to elevated levels of NDMA (N-nitroso dimethylamine), a suspected human carcinogen, above FDA limits.
• In November 2019, to expand their product line, major market players are focusing on product acceptance and launch. Talicia, treatment for Helicobacter pylori infection in adults.
• The company ‘RedHill Biopharma’ announced the commercial launch in the United States of Talicia, a capsule to treat H. pylori infection in patients in March 2020. The announcement made the company one of the leading pharmaceutical companies in the world.
• In March 2023, Onconic Therapeutics entered into a licensing agreement with Livzon pharmaceutical group for $127.5 million. The agreement has been made with an aim to develop and commercialize zastaprazan, a medication for GERD. 

DETAILED SEGMENTATION OF THE GLOBAL PEPTIC ULCER DRUGS MARKET INCLUDED IN THIS REPORT

This research report on the global peptic ulcer drugs market has been segmented and sub-segmented based on drugs type, ulcer, and region.

By Drug Type

• Proton Pump Inhibitors (PPIs)
• Anti-Histamines
• H2 Antagonists
• Antacids
• Antibiotics
• Others

By Ulcer Type

• Gastric Ulcers
• Duodenal Ulcer
• Esophageal Ulcer

By Region

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa